Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Gross Margin came in at 94.76% in Q1 2026, up 136.0% YoY from 40.15% in Q1 2025, and down 0.83% on a QoQ basis from 95.55% in Q4 2025.
Powered by 
Analysis
Zevra Therapeutics (ZVRA) Gross Margin (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 7 years of Gross Margin data on file, last reported at 94.76% in Q1 2026.
- Quarterly Gross Margin rose 136.0% year-over-year to 94.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 86.08% (up 727.0% YoY) and the FY2025 annual result came in at 84.52%, up 1593.0% from the prior year.
- Gross Margin fell to 94.76% in Q1 2026, from 95.55% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 98.4% in Q2 2022 to a low of 18.8% in Q2 2024.
- A 5-year average of 83.34% and a median of 94.82% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin sank 7321 bps — and 2025, when it jumped 5758 bps.
- Tracing ZVRA's Gross Margin over 5 years: stood at 95.45% in 2022, then dropped by 5 bps to 90.5% in 2023, then decreased by 2 bps to 88.63% in 2024, then increased by 8 bps to 95.55% in 2025, then fell by 1 bps to 94.76% in 2026.
- The last three Gross Margin figures came in at 94.76% (Q1 2026), 95.55% (Q4 2025), and 95.25% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Zevra Therapeutics | 734.60 Mn | 513.03 Mn | 38.18 Mn | 96.16% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 96.16% |
| Mar 31, 2026 | 94.76% |
| Dec 31, 2025 | 95.55% |
| Sep 30, 2025 | 95.26% |
| Jun 30, 2025 | 52.20% |
| Mar 31, 2025 | 93.41% |
| Dec 31, 2024 | 88.63% |
| Sep 30, 2024 | 37.76% |
| Jun 30, 2024 | 19.69% |
| Mar 31, 2024 | 94.89% |
| Dec 31, 2023 | 90.50% |
| Sep 30, 2023 | 95.03% |
| Jun 30, 2023 | 92.01% |
| Mar 31, 2023 | 96.06% |
| Dec 31, 2022 | 98.91% |
| Sep 30, 2022 | 95.09% |
| Jun 30, 2022 | 96.08% |
| Mar 31, 2022 | 99.80% |
| Dec 31, 2021 | 97.71% |
| Sep 30, 2021 | 100.00% |